ICU Medical, Inc. (ICUI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there is strong performance in IV Systems and consistent guidance for EBITDA and EPS, the decline in Vital Care revenue and management's vague responses about certain issues could cause investor uncertainty. The company's focus on reducing debt and maintaining higher price points is positive, but the lack of immediate financial impact from new hardware and unresolved issues in Vital Care tempers optimism. The market cap suggests moderate volatility, leading to a neutral prediction for the stock price movement.
Key Financial Performance
Revenue for Q1 $526 million, total company growth of 1% on an organic basis or minus 12% reported. The reported results are impacted by the mid-2025 creation of the Otsuka ICU Medical joint venture and resulting deconsolidation of IV Solutions from the income statement.
Gross margins Above 41%, driven by overall mix in infusion businesses. Sequential increase.
Adjusted EBITDA $99 million, same as last year. Year-over-year comparability impacted by deconsolidation of IV Solutions business ($6 million earnings in Q1 2025) and increase in tariff expense ($8 million year-over-year). These were offset by higher earnings from the core business ($14 million).
Adjusted EPS $1.97, compared to $1.72 last year, an increase of 15%. Reflects net interest expense of $16 million and an adjusted effective tax rate of 24%.
Free cash flow $28 million, reflecting strong quality of earnings and lower CapEx spending in Q1.
Consumables business revenue Grew 5% reported and 2% organic. Sequential decline from Q4 to Q1 was expected due to changing environment from December to January.
IV Systems business revenue Grew 8% reported and 6% organic. Record quarter in pumps. Dedicated sets followed the same trend as consumables, and capital sales were strong.
Vital Care revenue Decreased 14% on an organic basis and 59% reported due to the deconsolidation of IV Solutions. Impacted by discontinuation of certain SKUs.
Adjusted SG&A expense $112 million, representing approximately 21% of adjusted revenue.
Adjusted R&D expense $21 million, representing approximately 4% of adjusted revenue.
Restructuring, integration, and strategic transaction expenses $17 million, related primarily to IT systems integration and manufacturing plant consolidation projects. Sequential decline relative to Q4.
Debt $1.3 billion at the end of Q1.
Cash $288 million at the end of Q1.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
510(k) Clearances: Received two new 510(k) clearances for consumables: one for oncology line bonding connectors to IV bags and another for a revised disinfection cap.
LifeShield Safety Software: FDA approved the latest version with enhanced analytics, reporting, and safety features for infusion delivery.
IV Systems Growth: Achieved record revenue in infusion systems, with growth expected to be more balanced throughout the year.
Vital Care Adjustments: Exiting certain Japanese surgical commodities, which are non-core and have seen significant revenue decline.
Gross Margin Improvement: Adjusted gross margin increased to 41%, driven by favorable product mix and integration synergies.
Cost Management: Reduced restructuring and integration expenses, with further decreases expected later in the year.
Comprehensive Infusion Therapy Focus: Strategic goal to build the most comprehensive infusion therapy company, supported by R&D and capital investments.
Portfolio Optimization: Exploring strategic outcomes for Vital Care portfolio and exiting non-core product lines.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Volatility: The company faces risks from macroeconomic factors such as fluctuating oil and diesel prices, which could increase logistics expenses by approximately $10 million in 2026. This is a significant cost pressure that could impact profitability.
Regulatory Challenges: The FDA has increased testing requirements for new infusion pump submissions, leading to delays in product approvals. This could slow down the company's ability to bring new products to market and impact revenue growth.
Tariff Expenses: The company incurred $10 million in tariff expenses in Q1 2026, with full-year tariff expenses projected between $40 million to $50 million. Although there is some temporary relief, the uncertainty around future tariff frameworks poses a financial risk.
Supply Chain and Operational Costs: Higher oil and diesel prices, along with freight carrier cost pass-throughs, are expected to increase logistics expenses. Additionally, ongoing restructuring and integration activities, though decreasing, still represent a financial burden.
Product Line Challenges: The company is exiting certain underperforming product lines, such as Japanese surgical commodities, which have seen a revenue decline of over 50%. This could lead to short-term revenue losses and operational adjustments.
Vital Care Business Decline: The Vital Care segment decreased 14% organically and 59% reported due to deconsolidation and SKU discontinuations. This decline could impact overall revenue and profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For Q2, the company expects growth rates to return to historical levels. Organic growth in the IV Systems business is expected to continue at the current rate or above in the near term.
Vital Care Business Outlook: Sequential stability to improvement is expected organically, with revenue assumptions for the near term being flat to slightly down due to decisions aimed at improving profitability.
Product Development and FDA Approvals: The company received FDA approval for new versions of its LifeShield safety software and other consumables. However, additional testing is required for new hardware platforms, which may delay their clearance.
Full-Year Guidance: The company believes its previously provided full-year guidance is still applicable despite macroeconomic risks such as higher oil prices and evolving trade policies. Tariff expenses are expected to be slightly lower than initial estimates for the second and third quarters.
IV Systems Growth: Growth in IV Systems is expected to be more balanced throughout the year, rather than being back-half weighted as previously anticipated.
Integration and Remediation Activities: Cash consumed in integration and remediation activities is expected to materially decrease later in the year, with sequential reductions in Q2.
Long-Term Goals: The company aims to deliver at or above long-term revenue targets for core businesses, expand margins, and improve free cash flow generation. Investments in R&D and manufacturing assets are expected to support long-term growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the growth driver for Infusion Systems in the quarter?
A:The strongest growth driver for Infusion Systems was LVP (Large Volume Pumps).
Q:What is the timing expectation for the new hardware?
A:The company is working as fast as possible, with a couple of months needed for testing and analysis, followed by dialogue. They did not plan for anything meaningful financially for a while, as it typically takes 18 months to get going.
Q:Is Medfusion expected to be cleared first?
A:Yes, Medfusion is prioritized for testing first.
Q:How much of the $10 million year-over-year decline in Vital Care is related to the exit of the Japanese product line?
A:A small portion of the $10 million decline is related to the Japanese product line, which is still on the income statement but continuing to shrink.
Q:What is the full-year expectation for free cash flow?
A:The full-year guidance is to improve upon last year and be close to $150 million.
Q:What changed in the systems business to allow for more balanced performance throughout the year?
A:The company improved synchronization of installation resources and scheduling with customer needs, leading to more balanced performance rather than a back-half weighted dynamic.
Q:How material was January's weakness in hospital volume trends to the quarter?
A:The company does not have exact precision but noted that the difference aligns with historical sequential declines in Q1 over Q4.
Q:Did the resolution of the Smiths warning letter have any effect on the quarter?
A:The resolution of the 2021 warning letter is not believed to be correlated to commercial activities, and the company still has a subset of products under a 2025 warning letter.
Q:What is the customer pipeline for Plum Duo and Plum Solo in 2026 or the next 12 months?
A:The company is focusing on signed competitive situations and has an active and robust pipeline for competitive opportunities. Most of this year's business is from competitive share wins.
Q:What is the guidance for Infusion Systems growth?
A:The full-year guidance remains the same, with growth expected to be steadier across Q2 to Q4 rather than back-end weighted.
Q:What are the assumptions for logistics costs, oil prices, and tariffs in the guidance?
A:The company assumes $10 million higher logistics costs, some reduction in oil prices throughout the year, and offsets from lower tariffs (two-thirds) and operational efficiencies (one-third).
Q:Are higher price points for new pumps sticking?
A:Yes, the company believes the technology offering is in line with its value and is holding firm on higher price points.
Q:What is the impact of the Japanese product line exit on Vital Care revenue?
A:The Japanese product line has drifted down $10 million over the years, but the company did not provide specific quarterly guidance for its impact.
Q:Is the gross margin improvement sustainable?
A:The company believes there is still a 2-point opportunity to hit target gross margins and has been consistently improving over the last 7-8 quarters.
Q:Is the company reiterating its EBITDA and EPS guidance?
A:Yes, the company is reiterating its original guidance and highlighting the moving parts affecting it.
Q:Is there evidence of the replacement cycle for infusion pumps starting earlier?
A:Conversations about the replacement cycle are starting, but the real energy will be towards the end of the year, with the opportunity being more significant next year.
Q:Does the company have any commentary on share trends for ICU?
A:The company prefers not to comment on share trends, stating that results in the P&L should speak for themselves.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer to the question about how material January's weakness in hospital volume trends was to the quarter, stating they did not have exact precision. Additionally, they did not provide specific guidance on the impact of the Japanese product line exit on Vital Care revenue, describing it as 'hard to explain.'
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Currency peso
English sample
FDA bar
FDA testing
FDA volume
ICR
IEEPA refund
Section tariff
approval
clearance
consumables Infusion
delivery workflow
example
factor
impact
infection control
infusion delivery
infusion therapy
line expectation
mix
needle connector
oil diesel
organic
product development
risk opportunity
safety step
step infusion
submission
tariff expense
term goal
testing FDA
venture
version
ICUI Transcript
ICU Medical, Inc. (ICUI) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents a mixed picture. While there is strong performance in IV Systems and consistent guidance for EBITDA and EPS, the decline in Vital Care revenue and management's vague responses about certain issues could cause investor uncertainty. The company's focus on reducing debt and maintaining higher price points is positive, but the lack of immediate financial impact from new hardware and unresolved issues in Vital Care tempers optimism. The market cap suggests moderate volatility, leading to a neutral prediction for the stock price movement.
ICU Medical, Inc. (ICUI) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call summary indicates solid financial performance with increased EBITDA and EPS guidance, strong cash flow, and strategic debt management. Product development is on track, with no sales impact from pending clearances. Operational improvements are expected to enhance margins, and the company is optimistic about its backlog and product refresh cycle. Although tariffs impact costs, structural mitigation efforts are underway. The Q&A reveals a stable market environment and positive analyst sentiment, with no significant risks highlighted. Given the company's market cap, these factors suggest a positive stock price movement of 2% to 8%.
ICU Medical, Inc. (ICUI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
ICU Medical, Inc. (ICUI) Q3 2025 Earnings Call Transcript
Positive11-6
The company's Q3 results show strong financial performance with improved gross margins and EPS growth. The Consumables and IV Systems segments performed well, despite challenges in the Vital Care segment. Management's cautious optimism and strategic focus on growth areas like Consumables and Systems, coupled with efforts to mitigate tariff impacts, support a positive outlook. The market cap suggests moderate volatility, leading to a predicted positive stock price movement of 2% to 8%.
ICUI Slides
ICUI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
